

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 0 663 210 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
31.01.1996 Bulletin 1996/05

(51) Int Cl.⁶: A61K 31/445, C07D 491/22

(43) Date of publication A2:
19.07.1995 Bulletin 1995/29

(21) Application number: 94309771.7

(22) Date of filing: 23.12.1994

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE

(30) Priority: 28.12.1993 JP 350037/93


(71) Applicant:
SUMITOMO PHARMACEUTICALS COMPANY,
LIMITED
Osaka 541 (JP)

(72) Inventors:
• Ohashi, Naohito
Takatsuki-shi (JP)
• Fujiwara, Norio
Toyonaka-shi (JP)
• Ueda, Yutaka
Brookline, MA 02156 (US)

(74) Representative:
Cresswell, Thomas Anthony et al
London WC1R 5LX (GB)


(54) Tumor necrosis factor production inhibitors

(57) Use of a compound of formula (1) or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for preventing or treating a disease caused by a tumor necrosis factor:




(1)

wherein R¹ represents a hydrogen atom, an alkyl group, an alkenyl group, an acyl group or a group of formula:



wherein R⁷ represents a halogen atom, a hydroxyl group, an alkoxy group, an alkylthio group, a carboxyl group, an alkoxycarbonyl group, an aryloxy carbonyl group, a cyano group, an amino group, an alkylamino

group, a dialkylamino group, a cycloalkyl group, a heterocyclic group, an aromatic group or an aromatic heterocyclic group; X¹ represents a carbonyl group or a methylene group; and k represents 0 or an integer of 1 to 5, with the proviso that when X¹ is a carbonyl group and R⁷ is a hydroxyl group, or when X¹ is a methylene group and R⁷ is a hydroxyl group, an amino group, an alkylamino group or a dialkylamino group, k represents an integer of 1 to 5; and, each of A and B independently represents a methylene group or a group of formula:



wherein each of R² and R³ independently represents a hydrogen atom, an alkyl group, an alkoxycarbonyl group or a substituted alkyl group.

EP 0 663 210 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 94 30 9771

DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
A	ACTA UNIV.PALACKI.OLOMUC., FAC.MED., vol. 90, 1979 pages 5-14, 'Isolation and chemistry of alkaloids from plants of the genus papaver. LXXVI' * the whole document *	1-14
A,D	J.PHARM.PHARMACOL., vol. 45, no. 8, August 1993 pages 707-10, 'Ca++-channel blockade in rat thoracic aorta by crychine isolated from Cryptocarya Chinensis Hemsl.' * the whole document *	1-14
A	J.NAT.PROD., vol. 51, no. 4, 1988 pages 760-4, 'Some unusual pavine and isopavine alkaloids from Roemeria refracta' * the whole document *	1-14
A	J.NAT.PROD., vol. 53, no. 5, pages 1267-71, 'Neocaryachine, a new pavine alkaloid from Cryptocarya Chinensis, and NMR spectral properties of related alkaloids' * the whole document *	1-14
<div style="display: flex; justify-content: space-between;"> <div> <p>CLASSIFICATION OF THE APPLICATION (Int.Cl.6)</p> <p>A61K31/445 C07D491/22</p> </div> <div> <p>TECHNICAL FIELDS SEARCHED (Int.Cl.6)</p> <p>A61K C07D</p> </div> </div>		
The present search report has been drawn up for all claims		
Place of search	Date of completion of the search	Examiner
THE HAGUE	17 November 1995	Gerli, P
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document</p>		

EPO FORM 150 (01/92) (P/0401)